| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H17ClN2O4 |
| Molecular Weight | 372.802 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC2=C(C=C1)N(C(=O)C3=CC=C(Cl)C=C3)C(C)=C2CC(=O)NO
InChI
InChIKey=AJRNYCDWNITGHF-UHFFFAOYSA-N
InChI=1S/C19H17ClN2O4/c1-11-15(10-18(23)21-25)16-9-14(26-2)7-8-17(16)22(11)19(24)12-3-5-13(20)6-4-12/h3-9,25H,10H2,1-2H3,(H,21,23)
| Molecular Formula | C19H17ClN2O4 |
| Molecular Weight | 372.802 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Oxametacin (1-p-chlorobenzoyl-2-methyl-5-methoxy-3-indolylacethydroxamic acid) is a non-steroidal anti-inflammatory compound that exerts analgesic, antipyretic and anti-inflammatory properties. This drug has been claimed to be effective in the treatment of acute attacks of gout. In the antiproliferative test, oxametacin exhibited leukemic cell lines selectivity against the solid tumor cell lines. Oxametacin also exhibited inhibitory activity toward histone deacetylases and thus could be used as a lead compound in the further development of histone deacetylase inhibitors for anticancer therapy.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | ||||
| Primary |
